Nephrocare Health IPO price band has been fixed in the range of ₹438 to ₹460 per equity share of the face value of ₹2. The Nephrocare Health IPO listing date is scheduled for Wednesday 10 December and will close on Friday 12 December. The award to anchor investors for the Nephrocare Health IPO is scheduled to take place on Tuesday, December 9. The floor price is 219 times the face value that the equity shares carry and the cap price times the face value is 230 times the face value. The Nephrocare Health IPO lot size is 32 equity shares and thereafter in multiples of 32 equity shares. Nephrocare Health IPO has reserved not more than 50% of the shares in the public issue for qualified institutional buyers (QIB), not less than 15% for non-institutional Institutional Investors (NII), and not less than 35% of the offering has been reserved for retail investors. The employee portion is reserved equity shares of up to ₹35 million in aggregate. Tentatively, Nephrocare Health IPO basis of allotment of shares will be finalized on Monday, December 15 and the company will start refunds on Tuesday, December 16, while the shares will be credited to the demat account of allottee on the same day after refund. Nephrocare Health’s share price is likely to be listed on BSE and NSE on Wednesday, December 17. Nephrocare Health IPO Details The IPO comprises a fresh issue of shares totaling ₹353.4 crore along with an offer for sale (OVS) of 1.12 crore shares from the selling shareholders. In the OVS, the promoters—Investcorp Private Equity Fund II, Healthcare Parent, Investcorp Growth Opportunity Fund, and Edoras Investment Holdings Pte. Ltd—will sell shares along with other shareholders, including Investcorp India Private Equity Opportunity, International Finance Corporation, and 360 One Special Opportunities Funds. From the new issue, the company plans to allocate ₹129.1 crore for setting up new dialysis clinics in India, ₹136 crore for debt repayment, and the remaining amount for general corporate needs. Founded in 2009, NephroPlus operated a global network of 519 clinics, which included 51 clinics in the Philippines, Uzbekistan and Nepal, as of September 30, 2025. registrar. (more to come)